The 5-HT1B/1D/1F agonist eletriptan, at an oral dose of 80 mg, has been shown to be more efficacious than sumatriptan 100 mg and placebo in the treatment of migraine attacks with or without aura. Another commonly prescribed oral treatment for migraine attacks is Cafergot® (1 mg ergotamine tartrate with 100 mg caffeine per tablet). The efficacy, tolerability and safety of 40- and 80-mg doses of eletriptan and 2 tablets of Cafergot® were compared in a double-blind, randomised, placebo-controlled, parallel-group trial involving 733 migraine patients. Patients recorded symptoms at baseline (before treatment) and 1, 2, 4 and 24 h after dosing. Headache intensity was assessed on a 4-point scale (3 = severe pain, 2 = moderate pain, 1 = mild pain, 0 = no pain). Significantly more eletriptan-treated patients (80 mg, 68%; 40 mg, 54%) than Cafergot-treated patients (33%; p < 0.001) reported headache response (improvement from moderate-to-severe to mild or no pain) at 2 h. Substantially more eletriptan recipients reported no pain (80 mg, 38%; 40 mg, 28%; Cafergot, 10%; placebo, 5%; p < 0.001). Eletriptan headache response rates at 1 h were significantly higher (80 mg, 39%; 40 mg, 29%; Cafergot, 13%; placebo, 13%; p < 0.002 for each comparison). Both doses of eletriptan were significantly more effective than Cafergot in reducing nausea (p < 0.0001), photophobia (80 mg, p < 0.0001; 40 mg, p < 0.002), phonophobia (80 mg, p < 0.0001; 40 mg, p < 0.003) and functional impairment (p ≤ 0.001) at 2 h. Adverse events were generally mild or moderate and transient. This randomised trial shows that oral eletriptan is more efficacious in the acute treatment of migraine than oral Cafergot and is well tolerated.

Keywords:
Eletriptan, Cafergot, Migraine, Safety, Headache, Efficacy
1.
Rasmussen BK, Olesen J: Epidemiology of migraine and tension-type headache. Curr Opin Neurol 1994;7:264–271.
2.
Stewart WF, Lipton RB, Celentano DD, Reed ML: Prevalence of migraine headache in the United States: Relation to age, income, race, and other sociodemographic factors. JAMA 1992;267:64–69.
3.
Silberstein SD, Lipton RB: Overview of diagnosis and treatment of migraine. Neurology 1994;44(suppl 7):S6–16.
4.
Lipton RB, Stewart WF, von Korff M: Burden of migraine: Societal costs and therapeutic opportunities. Neurology 1997;48(suppl 3):S4–9.
5.
Diener H-C: A review of current treatments for migraine. Eur Neurol 1994;34(suppl 2):18–25.
6.
The Multinational Oral Sumatriptan and Cafergot Comparative Study Group: A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol 1991;31:314–322.
7.
Dahlöf C: Placebo-controlled clinical trials with ergotamine in the acute treatment of migraine. Cephalalgia 1993;13:166–171.
8.
Silberstein SD: The pharmacology of ergotamine and dihydroergotamine. Headache 1997;38(suppl 1):S15–25.
9.
Tfelt-Hansen P, Saxena PR, Dahlöf C, Pascual J, Lainez M, Henry P, Diener H-C, Schoenen J, Ferrari MD, Goadsby PJ: Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 2000;123:9–18.
10.
Maassen Van Den Brink A, Reekers M, Bax WA, Ferrari MD, Saxena PR: Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25–30.
11.
Tfelt-Hansen P, Paalzow L: Intramuscular ergotamine: Plasma levels and dynamic activity. Clin Pharmacol Ther 1985;37:29–35.
12.
Schmidt R, Fanchamps A: Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974;7:213–216.
13.
Milton KA, Allen MJ, Abel S, Jenkins VC, James GC, Rance DJ, Eve MD: The safety, tolerability, pharmacokinetics and pharmacodynamics of oral and intravenous eletriptan, a potent and selective ‘5-HT1D-like’ receptor partial agonist. Cephalalgia 1997;17:414.
14.
Milton KA, Allen MJ, Abel S, Grimwood VC, James GC, Rance DJ, Eve MD: The safety, tolerability and pharmacokinetics of oral eletriptan (UK-116,044) a potent and selective ‘5-HT1D-like’ receptor agonist. Cephalalgia 1996;16:368.
15.
Lacey LF, Hussey EK, Fowler PA: Single dose pharmacokinetics of sumatriptan in healthy volunteers. Eur J Clin Pharmacol 1995;47:543–548.
16.
Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC, Poole PH: Eletriptan in acute migraine. A double-blind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000;54:156–163.
17.
Cafergot® (ergotamine tartrate and caffeine) tablets. Package Insert. East Hanover, NJ, Novartis Pharmaceutical Corporation, 1999.
18.
Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(suppl 7):1–96.
19.
Färkkilä M, Diener H-C, Dahlöf C, Steiner TJ: A dose-finding study of eletriptan (UK-116,044) (5–30 mg) for the treatment of acute migraine. Cephalalgia 1996;16:387.
20.
Casagrande JT, Pike MC, Smith PG: An improved approximate formula for calculating sample size for comparing two binomial distributions. Biometrics 1978;34:483–486.
21.
Dunnet CW, Tamhane AC: Comparisons between a new drug and active and placebo controls in an efficacy clinical trial. Stat Med 1992;11:1057–1063.
22.
Steiner TJ: Efficacy, safety and tolerability of oral eletriptan (40 mg and 80 mg) in the acute treatment of migraine. Cephalalgia 1998;18:385.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.